Prostate Cancer Home > Trelstar and Breastfeeding
Trelstar (triptorelin pamoate) is only approved for use in men with prostate cancer, so its use is not recommended in women, including nursing women. It is unclear if this medication passes through breast milk, and no research has been done on nursing while using this drug. Because the drug affects hormone production, the manufacturer of Trelstar advises breastfeeding women to avoid it.
Trelstar® (triptorelin pamoate) is a prescription hormone medication used in the treatment of prostate cancer. It belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists reduce the amount of estrogen and testosterone made in the body.
It is unknown if Trelstar passes through breast milk. It is not approved for use in women, including women who are breastfeeding.
No research has been done on Trelstar and breastfeeding. Therefore, it is unknown if the medicine passes through breast milk. It is also unknown if the medicine has effects on breast milk production or on a nursing child.
Because of this lack of information, all potential problems cannot be ruled out. Although it is frustrating to have such little information available, it is important to remember that medications are rarely studied in breastfeeding women, as this would usually expose an infant, who will not directly benefit from the medication, to possible risks.
The manufacturer of Trelstar recommends that the drug not be used in breastfeeding women. Many medicines are passed through breast milk. Because Trelstar affects hormone production, it could potentially affect breast milk supply; it may also cause side effects in a nursing child. In addition, this medicine is only approved for use in men with prostate cancer.